Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Pharmaceutical preparation for hyperplasia of prostate

A technology for benign prostatic hyperplasia and pharmaceutical preparations, applied in the field of pharmaceuticals, can solve the problems of increased patient pain, ineffective curative effect, and side effects of patients, and achieve the effects of low cost, simple preparation, and reduced side effects

Inactive Publication Date: 2016-08-24
仁和堂药业有限公司
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Traditional Chinese medicine prescriptions in the prior art lack dialectics, the treatment cycle is long, the symptoms are not strong, the curative effect is not obvious, and it may even bring side effects to patients and increase the pain of patients. It has become a common problem to find effective and safe medicines from natural medicines. The problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical preparation for hyperplasia of prostate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] A pharmaceutical preparation for benign prostatic hyperplasia, which is prepared from the following raw materials:

[0031] Finasteride 1.2kg, Chinese herbal ingredients 1.3kg, starch 9.2kg, pregelatinized starch 9.2kg, lactose 13.5kg, microcrystalline cellulose 11.6kg, carboxymethyl starch sodium 2.5kg, 2% hypromellose pulp 25kg, magnesium stearate 0.15kg, get above-mentioned raw material, granulate according to conventional method, prepare 500,000 tablets.

[0032] The Chinese herbal medicine composition is prepared from raw materials of the following weight:

[0033] 40 parts of Guizhi, 40 parts of Anemarrhena, 40 parts of Shudi, 35 parts of Wang Buliuxing, 35 parts of Ligustrum lucidum,

[0034] 35 parts of epimedium, 35 parts of ginger, 35 parts of desmodium, 30 parts of almond, 30 parts of pepper,

[0035] 30 parts of curcuma, 30 parts of dodder, 28 parts of dandelion, 28 parts of frankincense, 28 parts of agarwood,

[0036]28 parts of plantain seed, 25 parts o...

Embodiment 2

[0047] Pathological test

[0048] Effects of Testosterone Propionate Induced Prostatic Hyperplasia Model in Castrated Rats

[0049] Experimental animal Wistar rats, male, weighing 120-150 grams, 40 rats, castrated under ether anesthesia (removal of testicles under aseptic operation), 30 rats in good condition were selected 3 days after the operation, and randomly divided into model groups , control group, and experimental group. Take another 10 rats, the operation process is the same as before, but the testes are not removed, and they are used as the control group (sham operation group).

[0050] Method of administration and dosage The test drug is administered orally (gavage), the control group (sham operation group) and the model group are given the same volume of distilled water, the experimental group is given the compound finasteride tablet prepared in Example 1, and the control group is given the marketed compound finasteride tablet. Finasteride tablets for sale. Dosi...

Embodiment 3

[0056] A total of 79 outpatients with benign prostatic hyperplasia were collected, aged 33-60 years, and the course of disease was 1-12 months. Randomly divided into: a treatment group of 40 cases, a control group of 39 cases. There was no significant difference in age, condition and other data between the two groups, and they were comparable.

[0057] Diagnose based on

[0058] Refer to "Diagnosis and Curative Effect Criteria of Traditional Chinese Medicine Syndrome"

[0059] Begin to urinate frequently, especially nocturnal urination, and gradually have difficulty urinating, with incessant urination, and in severe cases, there may be urinary retention or urinary incontinence.

[0060] The disease is more common in older men.

[0061] Digital rectal examination: hypertrophy of the seminal chamber, smooth surface without nodules, clear edges, medium hardness and elasticity, and the central sulcus becomes shallow or disappears.

[0062] B-ultrasound examination: the size of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical preparation for hyperplasia of prostate. The pharmaceutical preparation is prepared from the following raw materials: 2.5kg of finasteride, 9.2kg of starch, 9.2kg of pregelatinized starch, 13.5kg of lactose, 11.6kg of microcrystalline cellulose, 2.5kg of sodium carboxymethyl starch, 25kg of 2% hydroxypropyl methylcellulose pulp and 0.15kg of magnesium stearate; and the raw materials are granulated by a conventional method to prepare 500,000 tablets. The product provided by the invention realizes an obvious and stable treatment effect on hyperplasia of prostate and has a broad application prospect.

Description

technical field [0001] The invention belongs to the technical field of medicines, and in particular relates to a medicine preparation for benign prostatic hyperplasia. Background technique [0002] Prostatic hyperplasia is a common and frequently-occurring disease that seriously endangers human health, and it increases with age; and there are nearly 100 million patients in China, which is a disease that seriously endangers human physical and mental health and life expectancy. With the progress of human society and the aging of the population, the incidence of BPH is increasing year by year. According to statistics, the prevalence rate of severe BPH in the elderly aged 60-69 can reach 50%-60%, while the prevalence rate of elderly aged 70-80 is as high as 80%. There are many studies on the pathogenesis of benign prostatic hyperplasia, but the etiology has not yet been elucidated. The main symptoms of benign prostatic hyperplasia are as follows: 1. Frequent urination. Frequent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K36/9068A61P13/08
CPCA61K36/185A61K36/21A61K36/282A61K36/284A61K36/288A61K36/296A61K36/324A61K36/36A61K36/39A61K36/483A61K36/484A61K36/488A61K36/53A61K36/538A61K36/54A61K36/57A61K36/634A61K36/638A61K36/68A61K36/736A61K36/752A61K36/756A61K36/758A61K36/78A61K36/79A61K36/804A61K36/835A61K36/8945A61K36/8964A61K36/8968A61K36/9066A61K36/9068A61K2236/331A61K2236/333A61K2236/39A61K2300/00
Inventor 林祥宇郭增光杜玲杰
Owner 仁和堂药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products